Psoriasis can affect far more than the skin. New biologics like risankizumab target the IL-23 pathway, with trials showing high rates of skin clearance and sustained results for patients with moderate-to-severe plaque psoriasis.
Log In or Register as a healthcare professional to read the full article.
